# Arrowhead Pharmaceuticals Shares Rise on Positive Early Alzheimer's Trial Data

- URL: https://stocks.freetheai.org/news/arrowhead-pharmaceuticals-shares-rise-on-positive-early-alzheimer-s-trial-data-a586dc
- Published: 2026-10-14T15:36:25Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:ARWR](https://stocks.freetheai.org/symbols/NASDAQ-ARWR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Arrowhead Pharmaceuticals, Inc. (ARWR) reported encouraging early-stage clinical trial results for ARO-MAPT, its experimental treatment for Alzheimer's disease. In a Phase 1/2a study, patients receiving the drug experienced an average 73% drop in tau protein levels in cerebrospinal fluid after 105 days, with reductions reaching up to 85%. The drug was generally well tolerated with mostly mild side effects and no serious adverse events reported.

The results indicate that the therapy effectively targets tau protein build-up, a key marker linked to Alzheimer's and other neurological conditions. Arrowhead evaluated three dose levels, noting that the data supports a potential dosing schedule of once every three months. Beyond its Alzheimer's pipeline, the biotechnology firm holds roughly $1.57 billion in total cash resources as of June 30, 2026, helping fund treatments across cardiovascular, liver, and metabolic diseases.

Investors will be tracking regulatory discussions that Arrowhead has initiated for the trial. The company is actively enrolling patients with early Alzheimer's disease, with additional trial data expected in 2027. Shares of Arrowhead were trading up 1.66% at $59.09 following the update, though the stock remains down about 13% for the year.

## Key points

- Arrowhead's experimental Alzheimer's drug, ARO-MAPT, achieved an average 73% reduction in tau protein levels in a Phase 1/2a trial.
- The trial evaluated three dose levels and demonstrated potential for once-every-three-months dosing with mostly mild side effects.
- Arrowhead is continuing enrollment for patients with early Alzheimer's disease, with further data anticipated in 2027.
- Shares of Arrowhead Pharmaceuticals rose 1.66% to $59.09 following the announcement.

## Questions and answers

### What were the results of Arrowhead's Alzheimer's trial?

In a Phase 1/2a trial, Arrowhead's experimental drug ARO-MAPT reduced tau protein levels in cerebrospinal fluid by an average of 73% after 105 days.

### When will Arrowhead release more data on ARO-MAPT?

Arrowhead is continuing patient enrollment for early Alzheimer's disease and expects to release additional data in 2027.

### How does Arrowhead's ARO-MAPT drug work?

ARO-MAPT is designed to reduce the production of tau protein, which is linked to Alzheimer's disease and other neurological disorders.